Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Designer drugs.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book is intended to serve as quick reference handbook on so-called designer drugs. These new, mainly synthetic compounds are also often referred to as analogues of controlled substances. This new work provides a unique directory of 104 designer drugs. This class of drugs is rapidly growing in variety and number of compounds. Although identification, toxicology and other properties have been thoroughly investigated, their analogues and derivatives remain poorly documented. This book fills the gap. Data which is available is often contradictory and confused. This directory provides a criti

Designer drugs --- Hallucinogenic drugs.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Ephedrine --- Phenylpropanolamine --- Norepinephrine --- Designer Drugs --- Analysis. --- analysis.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This report presents the recommendations of a WHO Expert Committee responsible for reviewing information on dependence-producing drugs to assess the need for their international control. The first part of the report contains a summary of the Committee's evaluations of seven substances (dronabinol, oripavine, buprenorphine, butorphanol, ketamine, khat and zopiclone). The report also discusses the substances that were pre-reviewed (gamma-hydroxybutyric acid and tramadol) and recommended gamma-hydroxybutyric acid for critical review at a future meeting. Two substances (gamma-butyrolactone and 1,4

Substance abuse. --- Drug abuse. --- Designer drugs. --- Stereoisomers. --- Ephedrine.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

In this update from the EU Early Warning System, the EMCDDA aims to provide insights into what is happening with new psychoactive substances in Europe, based on data from the agency’s early warning and risk-assessment activities. This report covers the period from January 2016 until December 2017.

Drug monitoring --- Designer drugs --- Fentanyl --- Synthetic marijuana --- Drug abuse